HTB

Conference reports

A range of treatments for facial lipoatrophy

Autopsy evidence confirms that ARVs tackle CNS lesions

XI International HIV Drug Resistance Workshop, Seville, 2-5 July, 2002

Short resistance reports from Seville

New anti-HIV compounds discussed at the Seville HIV Drug Resistance Workshop and the Barcelona World AIDS Conference

Review of phenotypic resistance testing data presented at the XI International HIV Drug Resistance Workshop

XIV International AIDS Conference Barcelona, 7-12 July 2002

Bill Clinton and Nelson Mandela promise to lead peer education among political leaders as world looks for $10 billion a year to fight HIV/AIDS

South African activist unveils campaign to force compulsory licences

MSF study shows treatment in resource-poor settings is effective

‘Barcelona Declaration’ demands 2m poor people are treated in the next two years

Lives were lost as experts argued the merits of care versus prevention, says Stefano Vella

Peter Piot sets out the global political agenda in the fight against HIV/AIDS

Health should be a right, not a commodity, and medicine must be removed from the World Trade Organisation, argues key speaker

Governments must act to cut drug prices, says Kenya’s health minister

Civil society had to fight for universal access to AIDS drugs in Brazil

Coalitions of local NGOs can effectively demand access to medicines, reports MSF

Involvement of PLWHA is key to improving access to treatments

ART can successfully tackle advanced disease in resource poor settings, reports MSF

Investment in treatment and care significantly reduces company health and social expenditure in Abidjan

Financing the global response to the epidemic will cost $9.2 billion a year, according to one estimate

The Global Fund: what, where, how much?

Leading businesses spurn Global Fund

14 Caribbean governments sign cut-price drugs agreement with six pharmaceutical companies

Thailand offers low-cost transfer to African countries of technology for the local production of generic antiretrovirals

Informal market plays a role in distributing antiretrovirals but exposes clients to risks

Abacavir hypersensitivity reactions in patients who rechallenge after interruptions for reasons other than hypersensitivity

Prolonged CNS side-effects of efavirenz can be severe and lead to treatment discontinuation

Four drug regimen for infants

Study of MTCT programme finds resistance in women on two doses of monotherapy

Emergence of resistance in children treated with ddI/d4T after treatment to reduce MTCT

Correlates of fatigue in HIV disease

Optimum hydroxyurea dose determined

Management of people with treatment experience and drug resistance

HIV-associated malignancies in the HAART era: flickers of hope and understanding

Lopinavir/r exhibits sustained virologic response in antiretroviral-naïve patients: 3-year data

Patients will have options regarding T-20 (enfuvirtide) injection sites

The role of tenofovir in antiretroviral-naive patients

Treatment interruption strategy reports from the XIV International AIDS Conference

New data from clinical trials of antiretrovirals

Behind the headlines about vaccine research

9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Februrary 24-28 2002

New research points the way for future treatment of women with HIV

3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, 11-13 April 2002

Three studies compare gender differences in use of antiretrovirals

9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Februrary 24-28 2002

Study results shed light on cardiovascular risks: role of antiretrovirals and metabolism of lipids and sugars

Switch to abacavir improves lipoatrophy

Potential use of niacin to reduce intra-abdominal fat

Further benefits shown with New-Fill for facial atrophy

Lipodystrophy associated with lower CD4+ T cell counts

Treatment interruptions

Analysis of cells from long term non-progressors points the way to using vaccines and STIs to restore immune response to HIV

Symposium on T cell turnover and thymic function

New drugs: perhaps some genuine excitement this time

T20 and beyond: inhibition of HIV attachment and fusion at the 9th CROI

Pharmacogenetics predict abacavir hypersensitivity

Pregnancy: growing body of evidence supports treating maternal disease

Peripheral neuropathy update

41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 16-19 December 2001

Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients

Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir

Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients

Immune reconstitution more difficult with low baseline CD4+ T cell counts

HIV-1 may revert to less pathogenic strain a few days after starting HAART

Post navigation